CRISPR/Cas9 editing of NKG2A improves the efficacy of primary CD33-directed chimeric antigen receptor natural killer cellsTobias Bexte, Evelyn Ullrich, Beate Anahita Jung et al.|Nature Communications|2024Cited by 71
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell ImmunotherapyPhilipp Wendel, Evelyn Ullrich, Lisa Marie Reindl et al.|Cancers|2021Cited by 46
Immunotherapy with NK cells: recent developments in gene modification open up new avenuesLisa Marie Reindl, Evelyn Ullrich, Nawid Albinger et al.|OncoImmunology|2020Cited by 41
CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AMLNawid Albinger, Evelyn Ullrich, Tobias Bexte et al.|Blood|2022Cited by 22
P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.Nawid Albinger, Evelyn Ullrich, Tobias Bexte et al.|HemaSphere|2023Cited by 1